EVAX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-14.79%

1 Month

-21.31%

3 Months

61.80%

6 Months

-49.30%

1 Year

-64.79%

2 Year

22.03%

Key data

Stock price

$1.44

P/E Ratio

0.00

DAY RANGE

$1.36 - $1.55

EPS

N/A

52 WEEK RANGE

$0.80 - $9.80

52 WEEK CHANGE

-$63.64

MARKET CAP

17.007 M

YIELD

N/A

SHARES OUTSTANDING

5.576 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-27-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$74,737

AVERAGE 30 VOLUME

$62,621

Company detail

CEO: Per Norlén
Region: US
Website: evaxion-biotech.com
Employees: 60
IPO year: 2021

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Evaxion Biotech A/S identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma.

EVAX - Evaxion Biotech A/S